PHE885
CPHE885B12201
Phase 2 mab terminated
Quick answer
PHE885 for Multiple Myeloma is a Phase 2 program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Pharmaceuticals
- Indication
- Multiple Myeloma
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated